Health Systems Institute Homepage
Photo of the Molecular Science and Engineering buildingCISE labPhoto of Taryn Davis at APHA06 HSI Booth

Join HSI email list Join an HSI mailing list

HSI Intranet HSI Intranet

Health Systems Institute
Georgia Institute of Technology
828 West Peachtree Street, NW
2nd Floor
Atlanta, GA 30332-0477
404.385.8193 (phone)
404.385.7452 (fax)


Research

Seed Grant Profile

49

2007-2008 Program

Previous | Next

Evaluation and Modeling of Redox Regulation of NF-kappaB in Acute Lymphoblastic Leukemia cells: Role in Drug Resistance

There has been increasing interest in the relationship between the NF-kB anti-apoptosis signaling pathway and the generation of reactive oxygen species (ROS) in pediatric acute lymphoblastic leukemia (ALL) post-therapy. Our previous results suggest that ALL cells with high levels of constitutively activated NF-kB have increased resistance to ROS-generating chemotherapeutic agents like doxorubicin. In particular, we have studied two patient-derived ALL cells lines which show differential regulation of NF-kB-activation levels post-treatment with doxorubicin: EU-1 (drug-resistant line) shows high levels of activated NF-kB post-therapy in contrast to EU-3 (drug-sensitive).

We hypothesize that key redox buffering components protect ALL cells from ROS-generating agents by preventing ROS-mediated downregulation of NF-kB. This hypothesis is supported by studies showing increased intracellular glutathione is associated with poor prognosis in pediatric lymphoblastic leukemias. We will evaluate the effect of redox-buffering components on the level of ROS induced by doxorubicin in the two patient-derived cell lines (EU-1 and EU-3). We then will use differences between the cell lines to generate redox-balance computational models of dox-sensitive and dox-insensitive cells. This will permit cell-line specific simulation of redox-conditions and identification of variations in key redox enzyme levels involved in regulating NF-kB activation in the two model cell lines. These results may have clinical significance in elucidating the role of redox-regulatory components in creating resistance to important ROS-generating chemotherapeutic agents used to treat acute lymphoblastic leukemia.


Investigators: Melissa Kemp (GT/Emory, Biomedical Engineering), Harry Findley (Children's Healthcare of Atlanta/Emory, Pediatrics)

To the Georgia Tech homepageTo the Emory University homepage